全文获取类型
收费全文 | 194973篇 |
免费 | 2651篇 |
国内免费 | 75篇 |
专业分类
耳鼻咽喉 | 1432篇 |
儿科学 | 7184篇 |
妇产科学 | 3439篇 |
基础医学 | 19274篇 |
口腔科学 | 1971篇 |
临床医学 | 14184篇 |
内科学 | 35411篇 |
皮肤病学 | 894篇 |
神经病学 | 18293篇 |
特种医学 | 9498篇 |
外科学 | 31946篇 |
综合类 | 2607篇 |
一般理论 | 16篇 |
预防医学 | 19546篇 |
眼科学 | 3296篇 |
药学 | 10511篇 |
中国医学 | 661篇 |
肿瘤学 | 17536篇 |
出版年
2023年 | 161篇 |
2022年 | 376篇 |
2021年 | 781篇 |
2020年 | 411篇 |
2019年 | 627篇 |
2018年 | 22557篇 |
2017年 | 17773篇 |
2016年 | 19907篇 |
2015年 | 1480篇 |
2014年 | 1547篇 |
2013年 | 1756篇 |
2012年 | 8362篇 |
2011年 | 22388篇 |
2010年 | 19525篇 |
2009年 | 12144篇 |
2008年 | 20600篇 |
2007年 | 22767篇 |
2006年 | 1671篇 |
2005年 | 3231篇 |
2004年 | 4341篇 |
2003年 | 5185篇 |
2002年 | 3332篇 |
2001年 | 402篇 |
2000年 | 530篇 |
1999年 | 315篇 |
1998年 | 370篇 |
1997年 | 360篇 |
1996年 | 220篇 |
1995年 | 222篇 |
1994年 | 209篇 |
1993年 | 168篇 |
1992年 | 141篇 |
1991年 | 183篇 |
1990年 | 230篇 |
1989年 | 163篇 |
1988年 | 156篇 |
1987年 | 151篇 |
1986年 | 96篇 |
1985年 | 133篇 |
1984年 | 124篇 |
1983年 | 121篇 |
1982年 | 158篇 |
1981年 | 125篇 |
1980年 | 203篇 |
1979年 | 79篇 |
1978年 | 95篇 |
1977年 | 83篇 |
1976年 | 92篇 |
1974年 | 90篇 |
1938年 | 84篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Beata Gawdis-Wojnarska Marek Brzosko Jacek Fliciński Krzysztof Marlicz Teresa Starzyńska Rodney J Scott Jan Lubiński 《Hereditary cancer in clinical practice》2004,2(2):65-68
Gastric cancer is the second most frequently diagnosed malignancy worldwide and therefore represents a significant healthcare burden. Environmental and genetic factors are involved in the development of gastric cancer. To date only one clear genetic predisposition has been identified involving mutations in the E-cadherin gene. The disease phenotype in patients harbouring E-cadherin mutations appears to be specifically related to diffuse gastric cancer. Little is known genetically about the other forms of gastric cancer. Since there is a growing awareness about the necessity of early intervention criteria have been developed that aid the identification of hereditary forms of gastric cancer. The aim of the current study was to identify minimal inclusion criteria so that nuclear pedigree families can be provided with risk assessment and/or genetic testing.The results reveal that inclusion features described herein such as (a) gastric cancer diagnosed before 46 years of age; (b) two gastric cancers among first degree relatives diagnosed over the age of 50 are useful in identifying suspected hereditary gastric cancer patients. 相似文献
992.
993.
994.
995.
996.
997.
Mitch Dowsett 《Breast cancer research and treatment》2004,87(1):11-18
cDNA arrays and proteomic analyses have allowed the rapid identification of specific genes and proteins implicated in multiple
tumor types. These molecules must then be validated as clinically relevant prognostic and predictive markers, and this translational
research is best conducted in the context of clinical trials. Outcomes data and clinical specimens collected in the ‘Arimidex’,
Tamoxifen, Alone or in Combination (ATAC) study, for example, can now be used to compare the expression of biomarkers with
clinical outcomes. In this study, adjuvant tamoxifen and anastrozole (‘Arimidex’) were compared alone and in combination in
more than 9000 women with breast cancer. Anastrozole was found to be superior to tamoxifen in terms of disease-free survival,
time to recurrence, and reduction in the incidence of contralateral tumors. Importantly, tissue specimens from surgical excision,
local relapse, and contralateral breast cancer were collected and paraffin-embedded for storage. In the TA01 (TransATAC) program,
these specimens will be studied (after obtaining patient consent) using tissue microarrays; tissue biopsy cores 0.6 mm in
diameter will be removed from donor blocks and placed on recipient blocks, which will be sectioned to allow the simultaneous
analysis of the same samples for multiple biomarkers. These analyses can help determine differential benefits of treatment
with anastrozole or tamoxifen, depending on the expression of particular biomarkers in tumor cells. This research also should
clarify de novo and acquired resistance mechanisms, and the validation of relevant molecular pathways could guide the development of new
drugs. Ultimately, the TA01 program has the potential to favorably impact treatment choices for breast cancer.
This revised version was published online in August 2006 with corrections to the Cover Date. 相似文献
998.
Objective: To study the gene polymorphisms of GSTT1 and GSTM1 in nasopharyngeal carcinoma (NPC) patients and controls in an
incidental area to evaluate the relationship between specific genotype and genotype combinations of these polymorphisms with
the risk of NPC. Methods: Cases and controls all came from the Southwestern Guangxi. DNAs were extracted from their WBC. PCR
technique was used to calculate the deletion rate of the two detoxific enzyme genes. Results: In this high risk area of NPC,
the residents had high level deletion rates of 47.4% (64/135) Ml and T1 40.7% (55/135). The deletion rates were even higher
in NPC patients, 61.5% (56/91) for Ml and 59.3% (54/91) for T1 respectively. There were statistical significances compared
with control,P<0.05 andP<0.01 for Ml and T1 respectively. The difference was more significant in terms of combined Ml and T1 deletion between patients
and controlsx
2=12.533,P=0.002. Conclusion: The combined deletion of detoxific enzyme genes GSTM1 and GSTT1 may be an important genetic susceptible
factor for NPC in Guangxi.
Biography: DENG Zhuo-lin (1929-), male, professor of pathology, Guangxi Medical University, majors in tumor pathology. E-mail :zhuolin@hotmail.com 相似文献
999.
Anthony T C Chan Brigette B Y Ma Y M Dennis Lo S F Leung W H Kwan Edwin P Hui Tony S K Mok Michael Kam Lisa S Chan Samuel K W Chiu K H Yu K Y Cheung Karen Lai Maria Lai Frankie Mo Winnie Yeo Ann King Philip J Johnson Peter M L Teo Benny Zee 《Journal of clinical oncology》2004,22(15):3053-3060
PURPOSE: To assess the efficacy of neoadjuvant paclitaxel and carboplatin (TC) followed by concurrent cisplatin and radiotherapy (RT) in patients with locoregionally advanced nasopharyngeal carcinoma (NPC) and to monitor treatment response with plasma Epstein-Barr virus (EBV) DNA. PATIENTS AND METHODS: Thirty-one patients with International Union Against Cancer stages III and IV undifferentiated NPC had two cycles of paclitaxel (70 mg/m2 on days 1, 8, and 15) and carboplatin (area under the curve 6 mg/mL/min on day 1) on a 3-weekly cycle, followed by 6 to 8 weeks of cisplatin (40 mg/m2 weekly) and RT at 66 Gy in 2-Gy fractions. Plasma EBV DNA was measured serially using the real-time quantitative polymerase chain reaction method. Results All patients completed planned treatment. Response to neoadjuvant TC was as follows: 12 patients (39%) achieved partial response (PR) and 18 achieved (58%) complete response (CR) in regional nodes; five patients (16%) achieved PR and no patients achieved CR in nasopharynx. At 6 weeks after RT, one patient (3%) achieved PR and 30 patients (97%) achieved CR in regional nodes, and 31 patients (100%) achieved CR in nasopharynx; 29 patients (93%) had EBV DNA level of less than 500 copies/mL. Neoadjuvant TC was well tolerated, and the most common acute toxicity of cisplatin plus RT was grade 3 mucositis (55%). At median follow-up of 33.7 months (range, 7 to 39.3 months), six distant and three locoregional failures occurred. Plasma EBV DNA level increased significantly in eight of nine patients who experienced treatment failure but did not increase in those who did not. The 2-year overall and progression-free survival rates were 91.8% and 78.5%, respectively. CONCLUSION This strategy was feasible and resulted in excellent local tumor control. Serial plasma EBV DNA provides a noninvasive method of monitoring response in NPC. 相似文献
1000.
Marilyn J Borugian Samuel B Sheps Charmaine Kim-Sing Cheri Van Patten John D Potter Bruce Dunn Richard P Gallagher T Gregory Hislop 《Cancer epidemiology, biomarkers & prevention》2004,13(7):1163-1172
High levels of insulin have been associated with increased risk of breast cancer, and poorer survival after diagnosis. Data and sera were collected from 603 breast cancer patients, including information on diet and physical activity, medical history, family history, demographic, and reproductive risk factors. These data were analyzed to test the hypothesis that excess insulin and related factors are directly related to mortality after a diagnosis of breast cancer. The cohort was recruited from breast cancer patients treated at the British Columbia Cancer Agency between July 1991 and December 1992. Questionnaire and medical record data were collected at enrollment and outcomes were ascertained by linkage to the BC Cancer Registry after 10 years of follow-up. The primary outcome of interest was breast cancer-specific mortality (n = 112). Lifestyle data were analyzed using Cox proportional hazards regression models to relate risk factors to outcomes, controlling for potential confounders, such as age and stage at diagnosis. Data for biological variables were analyzed as a nested case-control study due to limited serum volumes, with at least one survivor from the same cohort as a control for each breast cancer death, matched on stage and length of follow-up. High levels of insulin were associated with poorer survival for postmenopausal women [odds ratio, 1.9; 95% confidence interval (CI), 0.7-6.6, comparing highest to lowest tertile, P trend = 0.10], while high dietary fat intake was associated with poorer survival for premenopausal women (relative risk, 4.8; 95% CI, 1.3-18.1, comparing highest to lowest quartile). Higher dietary protein intake was associated with better survival for all women (relative risk, 0.4; 95% CI, 0.2-0.8, comparing highest to lowest quartile). 相似文献